search
Back to results

Probiotics, Brain Structure and Psychological Variables (ProBrain01)

Primary Purpose

Depressive Symptoms, Anxiety, Stress

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Vivomixx® powder
Placebo powder
Sponsored by
Universitätsklinikum Hamburg-Eppendorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Depressive Symptoms focused on measuring Probiotics, Psychiatric Symptoms, Cognitive Function, Hippocampus, Oxytocin, Immunological Parameters

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy participants
  • age 18-40
  • informed consent for all parts of the study (including MRT)
  • none of the exclusion criteria (see below) fulfilled

Exclusion Criteria:

  • age < 18 or > 40 years
  • pregnancy or breastfeeding
  • left-handedness
  • degenerative or inflammatory diseases of the central nervous system
  • severe cognitive/ neuropsychological impairment
  • severe pain syndrome or other severe organic diseases
  • epilepsy
  • (past or present) psychiatric disorders
  • neurological disorder
  • severe diabetic polyneuropathy
  • malignancies/ cancer
  • cardiac insufficiency
  • arterial hypertension
  • heart attack/ stroke
  • severe hepatic or renal insufficiency
  • diseases of the hemopoietic system
  • alcoholism/ drug addiction
  • medical history of severe allergic or toxic reactions
  • current participation in drug trial
  • doubts about legal capacity/ capability of understanding
  • referral to institutions based on court/ official order
  • treatment with centrally acting medication (e.g. antipsychotics, antiepileptics, antidepressants, etc.)
  • non-removable metal pieces (aneurysm clips, artificial limbs, etc.) or implanted electronic devices (pacemaker, osmotic or other implanted pumps, cochlear implants, etc.)
  • claustrophobia
  • acute (respiratory) infection, physical uneasiness
  • tattoos in the head region, permanent make-up
  • non-removable piercings
  • chronic/ acute gastrointestinal diseases
  • vegetarianism, veganism
  • current intake of antibiotics or intake of antibiotics at any time point during the last 2 months
  • lactose intolerance
  • general focus on probiotic diet

Sites / Locations

  • Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

verum condition probiotics

placebo condition

Arm Description

The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.

In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.

Outcomes

Primary Outcome Measures

Changes in hippocampal volume, assessed via Magnet Resonance Imaging (MRI)
changes in hippocampal volume in verum experimental group (in comparison to placebo control)
Changes in functional brain activation during fMRI task
changes in functional connectivity (using BOLD signal) in hippocampal regions in verum experimental group (in comparison to placebo control) during pattern separation fMRI task
Changes in depression
changes in levels of depression, assessed with Beck's Depression Inventory - II Revised (BDI-II-R) sum score in verum experimental group (in comparison to placebo control)
Changes in spatial navigation
changes in test performance scores (number of correct responses, degree of accuracy measured as position hits) in the Tunnel task in verum experimental group (in comparison to placebo control)
Changes in Interleukin-6 (IL-6)
changes in IL-6 blood serum concentration levels in verum experimental group (in comparison to placebo control)
Changes in IL-1ß
changes in IL-1ß blood serum concentration levels in verum experimental group (in comparison to placebo control)
Changes in Tumor Necrosis Factor alpha (TNF-alpha)
changes in TNF-alpha blood serum concentration levels in verum experimental group (in comparison to placebo control)
Changes in Brain Derived Neurotrophic Factor (BDNF)
changes in blood serum level concentration of BDNF in verum experimental group (in comparison to placebo control)
Changes in verbal learning test performance
changes in verbal learning performance score, assessed with the Verbal Learning Memory Test (VLMT) in verum experimental group (in comparison to placebo control)
Changes in pattern separation fMRI task
changes in the pattern separation task performance (no. of correct responses to picture stimuli) in in verum experimental group (in comparison to placebo control)

Secondary Outcome Measures

Full Information

First Posted
January 26, 2018
Last Updated
February 7, 2021
Sponsor
Universitätsklinikum Hamburg-Eppendorf
search

1. Study Identification

Unique Protocol Identification Number
NCT03478527
Brief Title
Probiotics, Brain Structure and Psychological Variables
Acronym
ProBrain01
Official Title
Effects of Probiotic Bacteria on Brain Structure and Function and on Psychological Variables
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
January 8, 2018 (Actual)
Primary Completion Date
November 30, 2019 (Actual)
Study Completion Date
January 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitätsklinikum Hamburg-Eppendorf

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Theory and research on the gut-brain-axis emphasize complex interactions between the gut microbiota, immunological and hormonal responses, brain function, brain structure, as well as resulting behavioral manifestations, such as cognitive functions and mental illness. Probiotics are living micro-organisms that change the composition of the gut microbiota and hypothetically have a positive effect on the host's general health and well-being. Probiotic bacteria naturally occur in foods such as Sauerkraut, olives, and dark chocolate, and are currently also added to industrial products such as yogurt. Regarding the effect of probiotics on brain structure and function, animal studies have shown that the administration of probiotics in mice and rats was linked to neurogenesis in the hippocampus and an improvement of associated cognitive functions. The majority of these studies applied probiotics for 4 weeks. The substances used in these studies were often composed of several bacterial strains, suggesting that the neurogenic effect may not be reducible to a specific type of probiotic bacteria. Probiotics seem to be effective in improving memory abilities, including spatial and non-spatial memory, both in rodents and humans. Moreover, specifically regarding the beneficial effect of probiotics on anxiety, depression and stress, preliminary evidence in humans is compelling. However methodologically sound (randomized-controlled trial [RCT], 'blind') studies are still lacking. To sum up, the present study is going to be the first RCT with human participants that investigates structural and functional changes of the hippocampus through probiotic bacteria, using Magnet Resonance Imaging (MRI). In addition, the study aims at advancing research in the field by investigating the effects of probiotics on a broad spectrum of cognitive functions, particularly those associated with hippocampal activity (e.g. spatial memory, verbal memory). Furthermore, effects on several types of mental illness (e.g. anxiety, depression, stress) will be studied. Potential translatory mechanisms that may promote the aforementioned effects will be examined, i.e. changes in immunological parameters, 'brain derived neurotrophic factor' (BDNF), and oxytocin.
Detailed Description
A double-blind RCT intervention study will be conducted to investigate the effect of a probiotic dietary supplement vs. a placebo, taken by healthy human participants (N = 60) for 28 consecutive days. Both substances are administered in doses of 4.4g (powder) per day. The probiotic dietary supplement used in the present study is a freely available product (in powder form) sold under the name of Vivomixx®. Per 4.4g the powder contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. This product was chosen, because a similar supplement with an identical composition of bacteria as Vivomixx® was found to be linked to hippocampal neurogenesis in mice. The placebo powder has a similar taste and consistency as the verum (Vivomixx®) powder, but contains no probiotic bacteria. First, participants will be screened online for eligibility (T0). Before and after the 28-day intake period, participants are asked to perform several cognitive tests and fill out questionnaires (T1, T2) at our laboratory (ca. 2 - 2.5 hours). Afterwards, blood samples will be drawn (ca. 5 minutes) and a magnet resonance tomography (MRT) session (ca. 1 - 1.5 hours) will be conducted, where participants will perform an object pattern separation task in the scanner (T1, T2). Furthermore, a follow-up after 2 months (T3), including the same assessments as at T1 and T2, will be conducted. During the intake period participants will fill out a brief questionnaire on a weekly basis, which includes an assessment of state depression and anxiety, defecation (control item to rule out adverse effects), recent (start of) intake of medication, recent (onset of) intake of antibiotics, and recent inter-current illness (e.g. influenza). In addition, participants will record their food intake (protocol) for one week (7 consecutive days) during the intake period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Symptoms, Anxiety, Stress
Keywords
Probiotics, Psychiatric Symptoms, Cognitive Function, Hippocampus, Oxytocin, Immunological Parameters

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1 Verum group, receiving the probiotic Vivomixx® powder 1 Placebo group, receiving a placebo powder (similar taste and consistency as Vivomixx® powder)
Masking
ParticipantInvestigator
Masking Description
double blind
Allocation
Randomized
Enrollment
59 (Actual)

8. Arms, Groups, and Interventions

Arm Title
verum condition probiotics
Arm Type
Experimental
Arm Description
The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
Arm Title
placebo condition
Arm Type
Placebo Comparator
Arm Description
In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vivomixx® powder
Other Intervention Name(s)
probiotic dietary supplement
Intervention Description
Participants will take in a daily dose of 4.4g for 28 consecutive days
Intervention Type
Other
Intervention Name(s)
Placebo powder
Intervention Description
Participants will take in a daily dose of 4.4g for 28 consecutive days
Primary Outcome Measure Information:
Title
Changes in hippocampal volume, assessed via Magnet Resonance Imaging (MRI)
Description
changes in hippocampal volume in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in functional brain activation during fMRI task
Description
changes in functional connectivity (using BOLD signal) in hippocampal regions in verum experimental group (in comparison to placebo control) during pattern separation fMRI task
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in depression
Description
changes in levels of depression, assessed with Beck's Depression Inventory - II Revised (BDI-II-R) sum score in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in spatial navigation
Description
changes in test performance scores (number of correct responses, degree of accuracy measured as position hits) in the Tunnel task in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in Interleukin-6 (IL-6)
Description
changes in IL-6 blood serum concentration levels in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in IL-1ß
Description
changes in IL-1ß blood serum concentration levels in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in Tumor Necrosis Factor alpha (TNF-alpha)
Description
changes in TNF-alpha blood serum concentration levels in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in Brain Derived Neurotrophic Factor (BDNF)
Description
changes in blood serum level concentration of BDNF in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in verbal learning test performance
Description
changes in verbal learning performance score, assessed with the Verbal Learning Memory Test (VLMT) in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in pattern separation fMRI task
Description
changes in the pattern separation task performance (no. of correct responses to picture stimuli) in in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Other Pre-specified Outcome Measures:
Title
Changes in Oxytocin (OXT)
Description
changes in blood serum concentration levels of OXT in verum experimental group (in comparison to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in Processing speed or performance IQ
Description
changes in processing speed assessed by a digit-symbol test (BIS; Berliner Intelligenzskala) in verum experimental group (as compared to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in cognitive emotion regulation - functional emotion regulation
Description
changes in functional emotion regulation questionnaire sum score (as assessed with the Cognitive Emotion Regulation Questionnaire; CERQ) in verum experimental group (as compared to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in Sleepiness
Description
changes in sleepiness questionnaire sum score (ESS; Epworth Sleepiness Scale) scores in verum experimental group (as compared to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)
Title
Changes in cognitive emotion regulation - dysfunctional emotion regulation
Description
changes in dysfunctional emotion regulation questionnaire sum score (as assessed with the Cognitive Emotion Regulation Questionnaire; CERQ) in verum experimental group (as compared to placebo control)
Time Frame
at baseline (day 0) after intake period (day 28+) and at follow up (day 84+)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: healthy participants age 18-40 informed consent for all parts of the study (including MRT) none of the exclusion criteria (see below) fulfilled Exclusion Criteria: age < 18 or > 40 years pregnancy or breastfeeding left-handedness degenerative or inflammatory diseases of the central nervous system severe cognitive/ neuropsychological impairment severe pain syndrome or other severe organic diseases epilepsy (past or present) psychiatric disorders neurological disorder severe diabetic polyneuropathy malignancies/ cancer cardiac insufficiency arterial hypertension heart attack/ stroke severe hepatic or renal insufficiency diseases of the hemopoietic system alcoholism/ drug addiction medical history of severe allergic or toxic reactions current participation in drug trial doubts about legal capacity/ capability of understanding referral to institutions based on court/ official order treatment with centrally acting medication (e.g. antipsychotics, antiepileptics, antidepressants, etc.) non-removable metal pieces (aneurysm clips, artificial limbs, etc.) or implanted electronic devices (pacemaker, osmotic or other implanted pumps, cochlear implants, etc.) claustrophobia acute (respiratory) infection, physical uneasiness tattoos in the head region, permanent make-up non-removable piercings chronic/ acute gastrointestinal diseases vegetarianism, veganism current intake of antibiotics or intake of antibiotics at any time point during the last 2 months lactose intolerance general focus on probiotic diet
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Kühn, Prof. Dr.
Organizational Affiliation
Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie, UKE Martinistraße 52, 20246 Hamburg, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie
City
Hamburg
ZIP/Postal Code
20246
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27315483
Citation
Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, Costa-Mattioli M. Microbial Reconstitution Reverses Maternal Diet-Induced Social and Synaptic Deficits in Offspring. Cell. 2016 Jun 16;165(7):1762-1775. doi: 10.1016/j.cell.2016.06.001.
Results Reference
background
PubMed Identifier
24778631
Citation
El Aidy S, Dinan TG, Cryan JF. Immune modulation of the brain-gut-microbe axis. Front Microbiol. 2014 Apr 7;5:146. doi: 10.3389/fmicb.2014.00146. eCollection 2014. No abstract available.
Results Reference
background
PubMed Identifier
23384445
Citation
Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013 May;36(5):305-12. doi: 10.1016/j.tins.2013.01.005. Epub 2013 Feb 4.
Results Reference
background
PubMed Identifier
26523278
Citation
Liu J, Sun J, Wang F, Yu X, Ling Z, Li H, Zhang H, Jin J, Chen W, Pang M, Yu J, He Y, Xu J. Neuroprotective Effects of Clostridium butyricum against Vascular Dementia in Mice via Metabolic Butyrate. Biomed Res Int. 2015;2015:412946. doi: 10.1155/2015/412946. Epub 2015 Oct 7.
Results Reference
background
PubMed Identifier
26522841
Citation
Liu WH, Chuang HL, Huang YT, Wu CC, Chou GT, Wang S, Tsai YC. Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice. Behav Brain Res. 2016 Feb 1;298(Pt B):202-9. doi: 10.1016/j.bbr.2015.10.046. Epub 2015 Oct 29.
Results Reference
background
PubMed Identifier
27210745
Citation
Mohle L, Mattei D, Heimesaat MM, Bereswill S, Fischer A, Alutis M, French T, Hambardzumyan D, Matzinger P, Dunay IR, Wolf SA. Ly6C(hi) Monocytes Provide a Link between Antibiotic-Induced Changes in Gut Microbiota and Adult Hippocampal Neurogenesis. Cell Rep. 2016 May 31;15(9):1945-56. doi: 10.1016/j.celrep.2016.04.074. Epub 2016 May 19.
Results Reference
background
PubMed Identifier
28239408
Citation
Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. eCollection 2017. Erratum In: Ann Gen Psychiatry. 2017 Mar 7;16:18.
Results Reference
background
PubMed Identifier
27413138
Citation
Wang H, Lee IS, Braun C, Enck P. Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review. J Neurogastroenterol Motil. 2016 Oct 30;22(4):589-605. doi: 10.5056/jnm16018.
Results Reference
background

Learn more about this trial

Probiotics, Brain Structure and Psychological Variables

We'll reach out to this number within 24 hrs